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ABSTRACT 
Objective: Recombinant Human Erythropoietin (rhEPO) is strongly inferred to protect the cardiomyocytes from the reperfusion injury and our aim 
is to elucidate the cardioprotective effect and the exact mechanism behind the cardioprotection. 
Methods: Neonatal rat cardiomyocytes (NCM) exposed to Hypoxia/Reperfusion (H/R) with or without pretreatment using various concentrations 
of rhEPO. To determine the cell viability-MTT assay, Acridine orange and Ethidium Bromide (Ao/EtBr) staining was performed. To determine the 
reactive oxygen species (ROS) and mitochondrial membrane potential (Δψm), Dichlorofluorescein diacetate (DCF-DA) and Rhodamine-123 was 
used. To determine the signaling pathways Western blot analysis of pAkt, pp38 MAPK, cytochrome-c were performed.  
Results: rhEPO was found to reduce the cell death by stabilizing ROS significantly, Δψm, cytochrome c release, and caspase-3. rhEPO, increases the 
phosphorylation of p38 MAPK, Akt and BAD compared to H/R. Further myocytes blocked with Wortmannin (WT), and SB203580 showed increased 
caspase-3 activity.  
Conclusion: Hence we conclude from this study that rhEPO regulated the factors involved in reperfusion injury through modulation of Akt and p38 
MAPK pathways.  
Keywords: Neonatal rat cardiomyocytes, Reperfusion injury, Akt, p38 MAPK, rhEPO and BAD 




Heart Failure (HF) is a state in which the heart cannot provide 
sufficient cardiac output to satisfy the metabolic needs of the body. It 
is a significant wellbeing issue around the world [1]. HF due to 
myocardial infarction (MI) or ischemia/reperfusion injury (I/R) 
results in cardiomyocytes loss. This loss in cardiomyocytes is not 
only associated with apoptosis but also with necrosis [2-4]. During 
ischemia/hypoxia because of the lack of oxygen supply, the electron 
flow gets inhibited, and ATP utilization turns out to be inefficient [5]. 
Consequently, ATP produced during reperfusion causes partial 
reduction of oxygen to water producing reactive oxygen species 
(ROS), which results in damage to the electron transport chain [6,7]. 
Besides ROS, other factors which involved in reperfusion injury are 
mitochondrial membrane potential (Δψm), calcium (Ca2+
Erythropoietin (EPO) is a hypoxia-induced hematopoietic cytokine/ 
hormone, an erythroid precursor which causes cell proliferation, 
differentiation and stimulates erythropoiesis. Apart from 
erythropoiesis, EPO has a cardioprotective effect which increases 
the number of capillaries and mature vessels in infarcted hearts [9, 
10] and up-regulates the expression of angiogenic cytokines such as 
VEGF and angiopoietin-1 [11-13].  
) overload, 
and cytochrome-c release and caspase cascade activation [8].  
EPO (3000U/Kg) has been shown to induce stem cell recruitment 
and improves cardiac functions when injected by intra-cardiac 
injection [14]. EPO (10,000 U/kg/d) has a protective effect against 
cardiac remodeling after MI in in vivo mouse models [15]. EPO (1 to 
50 U/ml) protects HK-2 cells from H2O2
EPO (300 IU/kg i. v) is able to reduce oxidative stress and caspase-3 
activities in H
 induced cell death in a 
dose-dependent manner [16]. A study in rat cardiomyocytes showed 
protection against Angiotensin II-induced cardiomyocyte 
hypertrophy when EPO administered at a dose of 20 U/ml [17]. 
Moreover, EPO (5000  U/kg) was found to have an anti-apoptotic and 
anti-necrotic effects in the proximal convoluted tubule when 
exposed to hypoxia in in vitro in renal I/R injury [18].  
2O2
We have demonstrated in H9C2 cells that EPO decreases ROS, Δψ
 induced ischemia in H9C2 cells and rabbit models 
[19]. EPO also exerts a neuroprotective effect by attenuating the 
production of ROS and reducing the basilar artery vasoconstriction 
on neural, vascular endothelium [20]. 
m  
and intracellular Ca2+homeostasis via modulation of Akt pathway 
[21]. Furthermore, it is not known whether EPO has an influence on 
other factors involved in reperfusion injury, such as caspase activity 
and cytochrome-c release. We have hypothesized that EPO has an 
influence on caspase activity, and cytochrome-c release also through 
modulation of Akt and p38 MAPK pathways in neonatal rat 
cardiomyocytes (NCM). In the present study, we have therefore 
investigated the effect of recombinant human erythropoietin 
(rhEPO) on the apoptosis, necrosis, ROS, Δψm, 
MATERIALS AND METHODS 
caspase-3 activity, 
cytochrome-c release, Akt and p38 MAPK pathways.  
Isolation of neonatal rat cardiomyocytes  
Our research work on neonatal rat pups was carried out in strict 
accordance with the recommendations of CPCSEA (committee for 
the purpose of control and supervision on experiments on animals) 
guidelines for laboratory animal facility. Our protocol was approved 
by the institutional animal ethics committee (IAEC) of Anna 
University (Permit Number: CBT/AU/IAEC 2011-1). All surgery was 
performed under ethyl ether, and all efforts were made to minimize 
suffering. All our research work was done in Centre for 
Biotechnology, Anna University, Taramani Campus, Chennai. 
Male/Female rat pups (Sprague-Dawley) at the age of 1-3 d were 
sacrificed by ethyl ether. The hearts were removed and then cut into 
1-3 mm3 square pieces and followed the protocol as described in 
[22]. The cut up tissue was transferred to a 15 ml conical flask 
containing trypsin solution (0.08%, 0.5 ml per rat) and a small 
magnetic bead subjected to preconditioning on ice for 20 min. The 
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tissue was processed in the conical flask at 37 ˚C for 10 min, which 
was subjected to constant stirring (150-200 rpm). The supernatant 
was transferred to a 15 ml centrifuge tube, and trypsin activity was 
inhibited by adding a mixture of trypsin inhibitor and cold culture 
medium without Bromodeoxyuridine (BrdU), supplemented with 
10% fetal bovine serum (FBS). The cell pellet was formed by 
centrifuging at 1000 rpm for 5 min and resuspended in 2 ml warm 
culture medium. Depending on the amount of undigested tissue, 
trypsinization and centrifugation steps were repeated 4-5 times. 
Cells were harvested by centrifugation for 6 min at 1200 rpm and 
resuspended in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% FBS, plated in tissue culture flask and 
incubated at 37 ˚C at 5% CO2
Characterization of neonatal rat cardiomyocytes 
 for 2 h. This facilitates separation of 
neonatal cardiomyocytes (NCM) from the non-myocytes (fibroblast). 
NCM in the supernatant was plated on 0.1% gelatine coated dishes 
with coverslips inside and cultured in DMEM containing 0.1 mmol 
BrDu (5-Bromo-2-deoxyuridine). BrDu containing DMEM was 
replaced by DMEM+10% FBS after 48 h. Beatings NCM were video 
graphed on day 3 using Nikon Camera at 20X and 40X.  
Hematoxylin and eosin staining method 
NCM was stained with Hematoxylin and Eosin (HandE) to visualize 
the morphology of NCM clearly. The media were removed from 60 
mm culture dish and NCM were washed using 1X phosphate buffer 
saline (PBS). The appropriate volume of 2% paraformaldehyde was 
added to the sample and spread properly and kept for 30 min. 
Paraformaldehyde was removed after 30 min and hematoxylin was 
added and incubated for 8 min and washed with 1X PBS followed by 
95% ethanol wash. Eosin was added to the hematoxylin stained 
NCM and incubated for 1 min. Then HandE stained NCM were 
washed with 1X PBS followed by 95% ethanol. The stained samples 
were allowed to dry for 5-10 min and images were captured under 
phase contrast microscope using Nikon microscope.  
Immuno-staining method 
NCM were washed with 1X PBS and incubated for 10 min at 37 ˚C 
with 2% (v/v) paraformaldehyde. Paraformaldehyde was removed 
carefully and fixed NCM were washed 3 times with 1XPBS (5 min per 
wash). The sample was permeabilized with Triton X-100 (0.1%) for 
5-10 min at RT (room temperature) then washed in 1XPBS. Samples 
were incubated at 37 ̊ C for about 3-4 h with monoclonal Anti-α-
Sarcomeric Actinin (A7811) (Sigma-Aldrich) at a dilution of 1:200 in 
1X PBS at 37 ˚C. Samples were washed and incubated with 
biotinylated anti-mouse secondary antibodies at a dilution of 1:500 
dilutions (Santa Cruz Biotechnology) for 45 min at 37 ˚C. At the end 
samples were washed and incubated for 15 min at 37 ˚C with avidin-
conjugated 1:500 FITC (Fluorescein isothiocyanate) and images 
were captured using confocal microscopy (Carl Zessis, Zen 2010) 
with excitation 490 nm and emission 525 nm [23].  
Treatment of neonatal rat cardiomyocytes 
NCM were cultured to 70%-80% confluency and were allowed to 
grow in serum-free DMEM+0.1% BSA (bovine serum albumin) 
overnight. Normoxic control group or groups induced to H/R after 
treatment with or without two applications of rhEPO (10 U/ml, 15 
U/ml and 20 U/ml) was used in our investigation. The first 
application of rhEPO was accomplished 24 h before H/R. A second 
application of rhEPO immediately before induction of hypoxia and 
hypoxic conditions were induced by incubating NCM in an airtight 
chamber (94% N2, 5% CO2 and remaining 1% O2
MTT assay 
) for 8 h without 
serum and glucose in DMEM medium [23]. Reperfusion was induced 
for 16 h by replacing glucose containing DMEM+10% FBS for 
hypoxic medium. For some of the experiments, cells were treated 
with 20 U/ml of EPO alone in normoxic condition. In some 
experiments, 10 µM SB203580, p38 MAPK inhibitor and 1 µM 
Wortmannin (WT), PI3K/AKT inhibitor were added 30 min prior to 
each application of rhEPO. Control cells were maintained in 
DMEM+10% FBS throughout the duration of the experiments.  
NCM were cultured in 0.1% gelatine coated 96 well plates for about 
70-80% confluency. NCM were pretreated with different 
concentration (10 U/ml, 15 U/ml and 20 U/ml of rhEPO) and 
incubated for 24 h and followed the treatment as described in the 
treatment of NCM. The MTT [3-(4, 5-dimethylthiazole-2-yl)-2, 5-
diphenyltetrazolium bromide] were added to each well and 
incubated at 37 ˚C in a CO2
Detection of apoptosis and necrosis 
 incubator for 4 h [24]. Soluble yellow 
color MTT is reduced by mitochondrial succinyl dehydrogenase into 
insoluble purple formazan. The insoluble formazan product was 
dissolved in 50 µl DMSO and incubated for 10 min and read 
absorbance at 540 nm.  
Followed by the pretreatment NCM were washed with 1XPBS and 
collected by centrifugation. NCM were resuspended in 100 µl of 
1XPBS, 10 µl of the cell suspension were put on a glass slide and 
then mixed with 1 µl of 1 mg/ml Acridine orange (Ao) and 1 µl of 10 
µg/ml Ethidium Bromide (EtBr). The coverslip was placed over the 
glass slide and immediately viewed under a confocal laser scanning 
microscope at a wavelength of excitation 502 nm and emission 526 
nm for Ao and for EtBr excitation 510 nm and emission 595 nm [21]. 
Detection of mitochondrial membrane potential and ROS 
After pretreatment NCM were cultured on 0.1% gelatine coated 
coverslips were washed with 1XPBS and incubated with Rhodamine-123 
(5 µg/ml) and DCFH-DA (100 µM) reagent for 30 min in the dark at 37 
˚C. Samples were washed thrice with 1XPBS and then the fluorescence 
was measured using a confocal laser scanning microscope using 514 nm 
and 570 nm for Rhodamine-123 and DCF-DA respectively. Before that 
confocal laser scanning microscope adjusts to the laser power (2%), 
detector gain, and resolution (512x512) and focused it on 40X oil 
immersion. The same parameter is used for all sets of experiments [21]. 
Quantification of the fluorescence was done by using image J software 
and the corrected cell fluorescence (CTCF) was obtained using the 
formula, CTCF = Integrated Density–(Area of selected cell X Mean 
fluorescence of background readings).  
Western blot analysis 
NCM were cultured on gelatin (0.1%) coated autoclaved glass coverslips 
in 60 mm dishes and was treated under 8 h hypoxia and 30 min of 
reperfusion with or without EPO. Cells were kept on ice and washed 
thrice with cold 1XPBS. Proteins were solubilized and extracted with 50 
μl RIPA buffer (50 mmol Tris, pH 8.0, 150 mmol NaCl, 0.5% SDS, 1% 
Nonidet P40, 0.5% sodium deoxycholate, 1 mmol EDTA, 1X protease and 
phosphatase inhibitor cocktail (Cell Signaling technologies.,). The lysate 
was utilized to estimate protein content with the Bradford Assay 
Reagent. Equal amounts of protein (20-50 μg) from each sample were 
electrophoresed on a 12% SDS-polyacrylamide gel with running buffer 
and transferred to a nitrocellulose membrane as described in the Cell 
Signaling technology protocol. The transferred membranes were 
checked with ponceau and incubated with primary antibodies such as 
Akt, p-Akt, p38 MAPK, pp38 MAPK, BAD, p-BAD (1:1000 dilutions, Cell 
Signaling Technologies.,) for overnight incubation in 4 ˚C. They were 
again washed 3 times with 1xTBST (Tris-Buffered Saline and Tween 20) 
before incubating with matching secondary antibody (1:10 000) for 45 
min. The protein bands were developed with alkaline phosphatase 
substrate.  
Detection of cytochrome c releases into cytosol 
The release of mitochondrial cytochrome-c into the cytosol was 
measured according to the protocol described previously [25]. 
Cultured NCM were rinsed with 1XPBS and homogenized in 0.25 M 
sucrose, 20 mmol Tris-HCl, and 5 mmol EDTA, pH 7. The 
homogenates were centrifuged at 800 g, discarded the pellet and the 
supernatant was centrifuged at 8000 g for 10 min. The pellet 
contains the mitochondrial fraction and the supernatant contains a 
soluble cytosol-enriched fraction. The supernatant was collected to 
measure cytochrome c released into the cytosol and the pellet was 
resuspended for western blot analysis using anti-rabbit cytochrome-
c as described previously in Western blot analysis.  
Detection of caspase-3 enzymatic activity 
NCM were cultured in 0.1% gelatine coated 60 mm cell culture 
dishes for about 70-80% confluency. After induction of H/R with or 
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without pretreatment with rhEPO, myocytes were washed with 
1XPBS and lysed with cell lysis buffer. The enzymatic activity of the 
caspase-3 is measured by following the protocol given in the 
caspase-3 colorimetric assay kit, RandD systems. After that, the cell 
lysate was incubated for 10 min on ice and centrifuged at 10 000 x g 
for 1 min. The supernatant was transferred to a new tube and kept 
on ice. Then 50 µl of the supernatant was added to 50 µl of 2X 
Reaction buffer containing DTT in 96 well plates. At the end, 
reaction mixtures were incubated with 5 μl of DEVD-pNA (caspase-3 
colorimetric substrate) for 1–2 h. The caspase activities were 
quantified by using a spectrofluorometer using a wavelength of 405 
nm [26].  
Statistics 
Statistical data were analyzed using ANOVA followed by TUKEYs 
tests in Graph Pad Prism. For all the experiments, data are presented 
as means±SEM from three to five samples. Values of P<0.05 were 
considered as statistically significant.  
RESULTS 
Characterization of NCM 
The NCM were isolated from 2 d-old neonatal rats. The morphology 
of the NCM was examined under an inverted microscope (Nikon) 
(fig. 1A). The cells were stained with nuclear stain hematoxylin and 
cytoplasmic stain Eosin and viewed under the microscope (fig. 1B). 
The beating of the cells was also observed during the third day after 
isolation. The beating was recorded to be 61 beats per min. The 
isolated cells were also confirmed to be cardiomyocytes by indirect 
immunofluorescence assay using anti-α-sarcomeric actin antibody 
which is a specific cardiac marker and showed green color 
fluorescence (fig. 1C). 
  
 
Fig. 1: Characterization of neonatal cardiomyocytes 
 
rhEPO cell viability studies  
NCM demonstrated increased survival rates when maintained under 
normoxia or pretreated with 20 U/ml as compared to the NCM 
which were subjected to H/R alone. Cell viability was increased from 
45 % in H/R injured NCM to 83.5% of 20 U/ml rhEPO pretreated 
NCM. Data are presented as means±SEM of the ratios from five 
independent experiments.* denotes p<0.05 for analyses compared 
to H/R (fig. 2).  
 
Fig. 2: Pre-treatment of rhEPO Increases Cell Viability in H/R-
Induced NCM 
 
rhEPO inhibits apoptosis and necrosis in H/R-induced NCM  
To distinguish viable cells from apoptotic and necrotic cells, Ao and 
EtBr double staining method was used. Control and rhEPO treated 
myocytes stained uniform green color because they can maintain 
membrane integrity (fig. 3A and 3C). Whereas H/R-induced 
myocytes lost membrane integrity so EtBr could enter and 
intercalated with DNA. Late apoptotic myocytes showed bright 
orange nuclei and necrotic myocytes showed red nuclei as showed 
in the fig. 3B. Data are presented as means±SEM of the ratios from 
three independent experiments.* denotes p<0.05 for analyses 
compared to H/R.  
 
 
Fig. 3: Pre-treatment of rhEPO in H/R-induced NCM had 
uniformly green nuclei with intact plasma and nuclear 
membranes 
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rhEPO stabilizes Δψm and ROS in H/R-induced NCM 
In control and rhEPO treated myocytes, fluorescence emitted by 
Rhodamine-123 appeared only in the perinuclear region where the 
mitochondria is located as showed in the fig. 4A and 4C. DCFH-DA 
crosses the cell membranes and the mitochondrial membrane by 
deacetylation and oxidation. This is facilitated by esterases and ROS 
in the cytoplasm and mitochondria. In H/R-induced NCM, 
Rhodamine-123 fluorescence colocalized with DCF fluorescence not 
only the perinuclear region but also in the cytoplasmic region and 
there was an increase in DCF fluorescence in H/R when compared to 
rhEPO pretreated NCM (fig. 4B). Data are presented as means±SEM 
of the ratios from three independent experiments.* denotes p<0.05 
for analyses compared to H/R. Accordingly rhEPO stabilizes Δψm
 
 
and ROS in H/R-induced NCM.  
 




rhEPO induces phosphorylation of Akt 
Fig. 5A depicts the phosphorylation of Akt in H/R-induced myocytes. 
NCM pretreated with rhEPO post-H/R showed a significant increase 
in phosphorylation of AKT in lane 3 of pAkt as compared to cells 
exposed to H/R. Expression of AKT in the corresponding row is not 
altered. This increase in phosphorylation of AKT was blocked by WT. 
Data are presented as means±SEM of the ratios from three 
independent experiments. * denotes p<0.05 for analyses compared 
to H/R.  
 
 
Fig. 5: Western blot analysis demonstrating the effect of rhEPO 
on Akt 
 
rhEPO increases the phosphorylation of p38 MAPK 
Fig. 6A depicts the phosphorylation of p38 MAPK in H/R-induced 
myocytes. NCM pretreated with rhEPO showed an increase in p38 MAPK 
phosphorylation in lane 3 when compared to control and H/R. The 
phosphorylation of p38 MAPK was blocked by SB203580. Expression of 
p38 MAPK (loading control) in the corresponding row is not altered. 
Data are presented as means±SEM of the ratios from three independent 
experiments. * denotes p<0.05 for analyses compared to H/R.  
 
 
Fig. 6: Western blot analysis demonstrating the effect of rhEPO 
on p38 MAPK 
 
rhEPO increases the phosphorylation of BAD 
Fig. 7A depicts the phosphorylation of BAD in H/R-induced myocytes. 
The myocytes pretreated with rhEPO showed a significant increase in 
phosphorylation of BAD in lane 3 as compared to myocytes exposed to 
H/R without rhEPO pretreatment. Expression of BAD (loading control) 
in the corresponding row is not altered. Data are presented as 
means±SEM of the ratios from three independent experiments.* denotes 
p<0.05 for analyses compared to H/R.  
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Fig. 7: Western blot analysis demonstrating the effect of rhEPO 
on BAD 
 
rhEPO decreases cytosolic release of cytochrome-c 
Fig. 8A depicts the cytosolic and mitochondrial release of 
cytochrome-c in H/R-induced myocytes. rhEPO pretreated NCM 
showed decrease cytosolic release of cytochrome-c (cytosolic 
cytochrome-c, lane 3) and increased mitochondrial accumulation of 
cytochrome-c (mitochondrial cytochrome-c, lane 3) but NCM 
without rhEPO pretreatment showed increased cytosolic release of 
cytochrome-c (cytosolic cytochrome-c, panel 2) and decreased 
mitochondrial accumulation of cytochrome-c (mitochondrial 
cytochrome-c, lane 2). Data are presented as means±SEM of the 
ratios from three independent experiments.* denotes p<0.05 for 
analyses compared to H/R.  
 
 
Fig. 8: Western blot analysis demonstrating the effect of rhEPO 
on cytochrome-c 
 
rhEPO inhibits caspase-3 activity in NCM  
NCM were induced with H/R with or without rhEPO treatment and 
caspase-3 activity was measured. The caspase-3 activities were 
markedly elevated after H/R. Pretreatment with rhEPO prevented 
the caspase-3 proteolytic activations induced by H/R. Further 
myocytes blocked with WT and SB203580 showed increase caspase-
3 activity as showed in fig. 9. Data are presented as means±SEM of 
the ratios from three independent experiments.* denotes p<0.05 for 
analyses compared to H/R.  
 
Fig. 9: Pre-treatment of rhEPO decreases caspase-3 activity 
 
DISCUSSION 
We believe our study is the first to demonstrate that the rhEPO 
regulates the factors involved in reperfusion injury, such as ROS, 
Δψm, cytochrome-c release and caspase-3 activity and protects NCM 
from cell death. We also found that the regulation was mediated 
through the 
Reperfusion of coronary artery flow is imperative to resuscitate the 
hypoxic/ischemic myocardium. Timely reperfusion encourages 
cardiomyocyte rescue and decreases cardiac morbidity and mortality 
[27]. Reperfusion rescues myocytes inside ischemic areas of necrosis, 
however, it causes lethal damage to myocytes with serious ischemia-
induced metabolic disturbances [28]. It is known that ischemia and 
reperfusion-induced ventricular arrhythmias and post-ischemic 
myocardial dysfunction (myocardial stunning), microvascular and 
endothelial injury [29-31] leads to reperfusion injury. Further 
reperfusion injury involves myocyte damage through apoptosis and 
irreversible cell damage or necrosis [32,33]. Administration of EPO 
reduces necrosis in an ischemic myocutaneous tissue in a dose-
dependent manner [34]. EPO treatment before or at the start of ischemia 
has been demonstrated to decrease apoptosis and ventricular 
dysfunction after I/R injury [35-37]. However, a decrease in necrosis 
was thus induced to protect from reperfusion injury, and rhEPO was 
efficiently used in this study by showing a reduction in both apoptosis 
and necrosis caused by reperfusion injury. In support to our present 
study, a clinical trial showed an effective protection of EPO against tissue 
injury caused by both apoptosis and necrosis following 6 mo of human 
kidney transplantations [38].  
modulation of Akt and p38 MAPK.  
MPTP is the mega channel in the inner mitochondrial membrane it 
allows molecules of<1.5 kDa when it opens [39]. MPTP opening is of 
two sorts: one is transient or intermediate, and another is long-
lasting opening, this variation depends on the balance between the 
cellular inducers and inhibitors [40]. I/R causes long-
lasting/irreversible opening of MPTP and the major consequence of 
long-lasting MPTP opening is destabilization of Δψm, depletion of 
ATP and NAD+, increased ROS generation, swelling of mitochondrial 
matrix, release of accumulated Ca2+, outer mitochondrial membrane 
rupture and cytochrome-c release, which further activates caspase 
cascade and blocks the electron flow via the electron transport chain 
[39,41-42]. Inhibition of these factors was in turn inferred to 
attenuate cell death, and rhEPO was effectively used in our present 
study in demonstrating significant decreases in the levels of ROS 
production, cytochrome-c release, caspase-3 activation and 
stabilization of Δψm, 
Activation of Akt signaling pathway results in activation of 
antiapoptotic factors such as eNOS, p70S6K and also the inhibition 
of pro-apoptotic factors such as caspase, BIM, BAD and BAX [43]. 
EPO has been reported to protect acute neuronal injury through the 
phosphorylation of Akt, Bad, maintaining Δψ
in NCM upon exposure to H/R. EPO has been 
found to exert neuroprotective effects by attenuating the production 
of ROS and reducing the basilar artery vasoconstriction on neural 
vascular endothelium [20].  
m  and nuclear neuronal 
DNA integrity and simultaneously inhibiting caspase-1, 3 and 8 
activities [44]. In our study rhEPO pretreatment showed a protective 
effect by a decrease in caspase-3 activity, and the mechanism of 
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inhibition is inferred to be through the modulation of pro-survival 
signaling pathway Akt. Evidence for this mechanism was confirmed 
by blocking the Akt pathway using WT and an increased in caspase-
3 activity was observed and thus confirming that the effect is 
primarily due to phosphorylation of Akt.  
Previous studies have shown HPC (Hypoxic Preconditioning) 
induced neuroprotection in cerebral ischemic injury is through the 
phosphorylation of p38 MAPK pathway [45]. Evidence suggested 
that EPO and HPC target the same signaling pathway [46] and this is 
confirmed by blocking the EPOR during hypoxia, which results in 
reduced HPC-induced effects such as activation of caspase-3, 
increased expression of BCL-2 and cell survival [47]. Thus, the use of 
EPO as a “Chemical preconditioning” acts as an alternative to HPC 
for promoting cell survival in embryonic stem cells transplanted into 
the ischemic rat brain [46,48]. Our present data showed an increase 
in phosphorylation of p38 MAPK in rhEPO pretreated NCM 
confirmed the previous studies, that rhEPO protection against H/R 
in NCM through the phosphorylation of p38 MAPK. The 
phosphorylation of p38 MAPK was blocked with SB203580 (p38 
MAPK inhibitor) and decreased caspase-3 activity. 
One of the downstream targets of Akt is BCL-2-associated death 
promoter (BAD). BAD belongs to the BCL-2 family and it includes 
both anti-apoptotic proteins and pro-apoptotic protein. When Akt 
phosphorylates BAD, it forms the BAD-(14-3-3) protein homodimer 
and allows BCL-2 which is free to inhibit apoptosis triggered by BAX. 
BAD phosphorylation is anti-apoptotic, and dephosphorylation is 
pro-apoptotic [49].  
CONCLUSION 
In conclusion, we demonstrate that rhEPO prevents apoptosis and 
necrosis in NCM subjected to H/R injury through increased 
phosphorylation of Akt, BAD and p38 MAPK. Our study shows for 
the first time that rhEPO pretreatment maintains Δψm
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